Dr. Reddy’s Laboratories has issued a clarification regarding media reports that hackers defrauded the company of ₹21.6 million. In a regulatory filing with the NSE, the pharma major confirmed the incident but emphasized that it has no material impact on its financials or day-to-day operations.
Dr. Reddy’s Responds to Cyber Fraud Allegation, Assures Business Continuity
In response to recent media coverage, Dr. Reddy’s Laboratories Ltd has formally acknowledged a cyber fraud incident involving a financial loss of ₹21.6 million. The company submitted a clarification to the National Stock Exchange (NSE) under Regulation 30 of SEBI’s LODR Regulations, stating that the matter is under investigation and necessary actions have been initiated.
The company emphasized that the incident does not affect its core operations or financial stability. It also reiterated its commitment to cybersecurity and internal controls, noting that preventive and corrective measures are being reinforced to avoid future breaches.
Key highlights
-
Dr. Reddy’s confirms ₹21.6 million fraud incident in NSE filing
-
Company states the event has no material impact on operations or financials
-
Internal investigation and remedial actions are underway
-
Cybersecurity protocols being reviewed and strengthened
-
Clarification issued under SEBI LODR Regulation 30
Sources: NSE India, Dr. Reddy’s Laboratories Regulatory Filing, Economic Times, Business Standard, Moneycontrol